Theravance Inc news

   Watch this stock
Showing stories 1 - 10 of about 97   

Articles published

THRX 18.06 -0.03 (-0.17%)
price chart
Theravance Inc (THRX) Jumps 6.09% on February 25
Theravance Inc ($THRX) was among the biggest gainers on the Russell 2000 for Wednesday February 25 as the stock popped 6.09% to $18.12, representing a gain of $1.04 per share.
Theravance, Inc. Announces Cash Dividend of $0.25 per Share Payable to ...
SOUTH SAN FRANCISCO, CA, Feb 23, 2015 (Marketwired via COMTEX) -- Theravance, Inc. THRX, -4.06% ("Theravance") today announced that the company's Board of Directors has declared a $0.25 per share cash dividend to be paid on March 31, 2015 to ...
Theravance Is Now Providing Better Visibility
Only 6 days after the recent investor conference, with most of the news on the drug launches already published by partner GSK (NYSE:GSK), investors did not have to expect any great surprises from yesterday's Theravance (NASDAQ:THRX) Q4 earnings ...
Theravance Reports In Line Loss in Q4, Revenues Increase  Zacks.com
Theravance Reports Fourth Quarter and Full Year 2014 Financial Results  MarketWatch
Theravance Inc Registers High Short Percent of Float
Theravance Inc (NASDAQ:THRX): Each share of Theravance Inc is priced at $10.68, which is 67.5% below the 52-week high.
Shares of Theravance Inc Sinks by -4.33% for the Week  Ashburn Daily
Zacks Rating Disclosure on Theravance Inc  Rock Hill Daily
Revenue Update on Theravance Inc
Theravance Inc (NASDAQ:THRX) announced the earnings results for Fiscal Year 2014 and Quarter 4. The results came in during after-hours on February 18,2015.
Price Target Update on Theravance Inc  Bar and Graph Report
Theravance Trading Up 5.6% After Dividend Announcement (THRX)  WKRB News
Zacks Long Term Rating Update on Theravance Inc
Theravance Inc (NASDAQ:THRX) is a hold, according to the latest average broker rating of 3.26. The number of analysts in this rating is 5. Research Analysts at Zacks has the counter a rating of 3, which implies that the firms recommendation is Neutral ...
Theravance Royalty Revenue Forecast
After another three months of investors panicking over the ongoing rout in Theravance (NASDAQ:THRX) shares, happening without major news, the company's commercial partner GSK (NYSE:GSK) has now provided an update on actual results.
Theravance Announces FDA Advisory Committee to Review BREO(R) ELLIPTA ...  Sierra Leone Times
Theravance: Notes From The Leerink Global Healthcare Conference (THRX)
Speaking at the Feb.12 Leerink Global Healthcare Conference, Michael Aguiar, the CEO of Theravance (NASDAQ:THRX), provided some further insights into the ongoing product launches of Breo/Relvar and Anoro and their present and expected future sales ...
Company Shares of Theravance Inc Rally 22.69%
Shares of Theravance Inc (NASDAQ:THRX) rose by 22.69% in the past week and 54.67% for the last 4 weeks. In the past week, the counter has outperformed the S&P 500 by 21.92% and the outperformance increases to 50.38% for the last 4 weeks.
Theravance Price Target Raised to $17.00 (THRX)  Ticker Report
Stocks News Alert: Cover-All Technologies (NYSEMKT:COVR), Maxwell ...  Gaining Green
Theravance Inc (THRX) is Trading Lower on Unusual Volume for February 19
Theravance Inc ($THRX) experienced unusually high volume on Feb. 19, as the stock [gained/lost] 10.27% to a closing price of $17.07.